Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nbqx SCHEMBL29412437 | 1.00 | MAPT (0.74) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| Nbqx SCHEMBL26985644 | 0.99 | MAPT (0.73) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| Nbqx SCHEMBL30728067 | 0.99 | MAPT (0.73) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| Nbqx SCHEMBL2230845 | 0.92 | MAPT (0.65) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL9341166 | 0.90 | KMT2A (0.61) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL28120662 | 0.85 | KMT2A (0.61) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| Nbqx SCHEMBL20501770 | 0.85 | MAPT (1.00) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL9670143 | 0.84 | KDM4E (0.52) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| Nbqx SCHEMBL29985796 | 0.84 | MAPT (0.98) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL5044934 | 0.81 | MAPT (0.52) | MAPTKDM4EKMT2AHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 755 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132511-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2024-04-25 | — | — | US | claimed |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-09-28 | — | — | US | claimed |
| US-20220387426-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LTD (NZ) | 2022-12-08 | — | — | US | claimed |
| US-20220354808-A1 | GLYCOLIC ACID PROTECTS AGAINST ISCHEMIC INSULTS | PAN MONTOJO FRANCISCO (DE) | 2022-11-10 | — | — | US | claimed |
| EP-3377055-B1 | GLYCOLIC ACID PROTECTS AGAINST ISCHEMIC INSULTS | PAN MONTOJO FRANCISCO (DE) | 2021-10-13 | — | — | EP | claimed |
| EP-3024463-B1 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING AUTISM SPECTRUM DISORDERS AND NEURODEVELOPMENTAL DISORDERS | NEUREN PHARMACEUTICALS LTD (NZ) | 2020-03-25 | — | — | EP | claimed |
| US-20180325849-A1 | GLYCOLIC ACID PROTECTS AGAINST ISCHEMIC INSULTS | PAN MONTOJO FRANCISCO (DE) | 2018-11-15 | — | — | US | claimed |
| EP-3377055-A1 | GLYCOLIC ACID PROTECTS AGAINST ISCHEMIC INSULTS | Pan-Montojo, Francisco (DE) | 2018-09-26 | — | — | EP | claimed |
| US-20180140601-A1 | Neuroprotective Bicyclic Compounds and Methods for Their Use in Treating Autism Spectrum Disorders and Neurodevelopmental Disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2018-05-24 | — | — | US | claimed |
| US-9867823-B2 | Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2018-01-16 | — | — | US | claimed |
| EP-1100504-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | Eisai Co., Ltd. (JP) | 2001-05-23 | — | — | EP | claimed |
| US-6172043-B1 | GENETIC ENGINEERED POLYPEPTIDE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-01-09 | — | — | US | claimed |
| WO-2000071102-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2000-11-30 | — | — | WO | claimed |
| EP-1015013-A1 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY beta-AMYLOID PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-07-05 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| WO-2000001376-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | EISAI CO., LTD (JP) | 2000-01-13 | — | — | WO | claimed |
| WO-1998030229-A1 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY β-AMYLOID PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1998-07-16 | — | — | WO | claimed |
| WO-1994022446-A1 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF NEURONAL CELL DEATH | NOVO NORDISK A/S (DK) | 1994-10-13 | — | — | WO | claimed |
| US-4889855-A | ADMINISTERING GLUTAMATE ANTAGONIST TO INHIBIT HYPERACTIVITY OF EXCITATORY NEUROTRANSMITTERS | A/S FERROSAN (DK) | 1989-12-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132511-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | COMT, HSD17B3, HSD3B1 | MAPT 3291/4885KDM4E 3101/4885KMT2A 901/4885 |
| US-20180140601-A1 | Neuroprotective Bicyclic Compounds and Methods for Their Use in Treating Autism Spectrum Disorders and Neurodevelopmental Disorders | GRIN2C, GRIN2D, GRIN2A | MAPT 762/4885KDM4E 2626/4885KMT2A 1533/4885 |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | MAPT 309/4885KDM4E 2713/4885KMT2A 500/4885 |
| US-20220387426-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | MAPT 309/4885KDM4E 2713/4885KMT2A 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.